DIBENZOAZEPINE COMPOUNDS FOR USE IN THE TREATMENT OF NEISSERIA AND RETROVIRUS INFECTIONS
Patent Information
- Application Number
- DE602019085133
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2019-09-30
- Publication Date
- 2026-05-20
- Estimated Expiration
- 2039-09-30
AI Technical Summary
Current treatments for infections caused by pathogens that interact with complement receptor 3 (CR3)-expressing cells, such as Neisseria species and retroviruses, are inadequate in effectively inhibiting the binding and entry of these pathogens into host cells.
Development of non-carbohydrate, small molecule ligands, particularly dibenzoazepine compounds, that specifically target the alpha subunit I-domain of CR3 to inhibit the interaction of pathogens with CR3-expressing cells, thereby preventing binding and entry.
The dibenzoazepine compounds effectively inhibit the adherence and replication of pathogens like Neisseria and retroviruses on host cells, demonstrating significant reduction in infection levels and potential for therapeutic applications.